Stabilizing the volume of exudative fluid, including subretinal fluid, may help maximize anti-VEGF treatment outcomes for patients with nAMD.
Unlocking Precision Medicine in RVO: When Anti-VEGF Therapy Isn’t Effective
Although anti-VEGF therapy is the current gold-standard treatment for retinal vein occlusion, not all patients respond to it. A study has found that volume of intraretinal fluid, among other factors detectable with optical coherence tomography, may help predict treatment response.
DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD
Standard treatment for nAMD involves repeated anti-VEGF injections. A recent study has found that an investigational therapy, administered through a bioerodible insert in the vitreous cavity, reduced treatment burden by 74% in one year.
Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration
Faricimab, a new drug for nAMD, offers patients similar benefits at 16-week intervals as aflibercept at eight-week intervals, a study shows.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Even Brief Delays in Intravitreal Injection Can Cause Vision Loss
Patients with diabetic eye disease or vein occlusion lost more vision than patients with age-related macular degeneration when they missed an intravitreal injection during the COVID-19 shutdown.
Influence of Baseline Factors on Time to Resolution of Diabetic Macular Edema Following Anti-VEGF Therapy
Study finds that patients with more severe diabetic retinopathy have faster resolution of diabetic macular edema after anti-VEGF treatment than patients with less severe diabetic retinopathy.
Retinal Leakage Pattern and Vascular Tortuosity May Predict Durability of Anti-VEGF Therapy
Study associates leakage patterns and tortuosity in retinal blood vessels with anti-VEGF therapy interval tolerance in patients with diabetic eye disease or retinal vein occlusion.
Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic
A lapse in anti-VEGF therapy can cause an irreversible decrease in visual acuity in neovascular age-related macular degeneration.
Predicting Visual Acuity Response to Anti-VEGF Therapy in Macular Edema Secondary to Retinal Vein Occlusion
Study shows that baseline presence of and changes in DRIL burden during the course of disease in RVO is a useful prognostic indicator for VA and can help guide treatment with anti-VEGF therapy.